modelA10BJ01

Diagram of A10BJ01

Extends from Pharmacokinetic.Models.PK_2C.

Information

name:Exenatide
ATC code:A10BJ01
route:subcutaneous
compartments:2
dosage:10mg
volume of distribution:28.3L
clearance:9.1L/h
other parameters in model implementation

Exenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is available in both twice-daily injection (Byetta) and long-acting once-weekly (Bydureon) formulations. Exenatide is approved and widely used today.

Pharmacokinetics

Pharmacokinetic parameters reported from healthy subjects and patients with type 2 diabetes after subcutaneous administration of 5 or 10 mcg exenatide. Single- and multiple-dose two-compartment models have been used. Data below reflect findings from key clinical studies and FDA labeling references.

References

  1. Cirincione, B, & Mager, DE (2017). Population pharmacokinetics of exenatide. British journal of clinical pharmacology 83(3) 517–526. DOI:10.1111/bcp.13135 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27650681

  2. Cirincione, B, et al., & Mager, DE (2017). Population Pharmacokinetics of an Extended-Release Formulation of Exenatide Following Single- and Multiple-Dose Administration. The AAPS journal 19(2) 487–496. DOI:10.1208/s12248-016-9975-1 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27896683

  3. Zhao, X, et al., & Soon, D (2008). Exenatide pharmacokinetics in healthy Chinese subjects. International journal of clinical pharmacology and therapeutics 46(9) 459–465. DOI:10.5414/cpp46459 PUBMED:https://pubmed.ncbi.nlm.nih.gov/18793576

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)